Uncategorized – Boundary Capital

Boundary Capital invests in VR training innovation Bodyswaps

March 7, 2023adminUncategorized

We are delighted to announce that Boundary Capital has invested in Bodyswaps who are transforming soft skills training through Virtual Reality and AI. The market opportunity for them is vast and their growth reflects their success. Their 2022 revenues, > £1mln, were 4.5 times 2021 with over £800,000 of that as recurring revenue. Currently they...

Boundary invests in ground breaking, ethical weedkilling tech Weedingtech

July 21, 2022adminUncategorized

We are delighted to announce our first investment from the Impact Life EIS Fund that we closed at the end of March. Many of you will be aware of the controversies around Glyphosate, (Roundup), the weedkiller. It is banned in the EU from December of this year and will stop being sold in the US...

Watch again: Investing in COP26 – Your Planet Needs You!

December 15, 2021adminUncategorized

Our most recent webinar looks at the crucial role private investors have in achieving the goals of COP26. We also discussed whether the UK is a good place for this type of investment and took a brief look at some current opportunities.

Is Sustainable Investing growing too fast?

September 28, 2021adminUncategorized

In the last 4 years global sustainable assets have increased from 5% of total global assets to over 10%. And, according to research by Bloomberg, will hit $53 trillion or 33% by 2025. More good news is found in research by Charles Stanley showing out performance by Sustainable Responsible Investment funds compared to non-SRI funds...

Boundary Board member backs first dedicated life sciences crowdfunding platform

September 26, 2017adminUncategorized

Adrian Parton, MBE, of Boundary Capital has backed Capital Cell, Europe’s first dedicated Life Sciences crowdfunding platform. Capital Cell works with companies whose technology is based on biology or healthcare to secure the investment they need to progress their innovative, potentially life-changing ideas. Capital Cell’s model is to support early stage companies, with seed stage...

Boundary Capital in the Press: Angel News, How ‘Mammalian Investing’ is taking the world of early tech investing by storm

July 17, 2017adminUncategorized

It’s easy to see how early-stage tech VC investing can make arguably the largest returns. If you get it right investing in a disruptive business like WhatsApp or Alibaba can generate huge exits: a whopping $22Bn and $25Bn respectively (Sequoia Capital turned $60 million into $3 billion thanks to WhatsApp). And not just in The...

Event: Boxing Clever – Techniques for early stage technology investing, to harness high growth whilst reducing risk

January 31, 2017adminUncategorized

Investors are looking for alternative strategies and techniques to improve earnings and reduce risk. We will look at how businesses can optimise their business model and gain traction for long-term sustainable growth – for the investor this means less risk, less capital needed and plenty of added value. Who is the event for? This event...

Case study: Desktop Genetics

June 29, 2016adminUncategorized

Gene editing is one of hottest areas of life sciences. Many scientists are working towards using CRISPR technology to provide genetic solutions to conditions by literally editing the DNA in the genes. Desktop Genetics provides gene editing software (SaaS and on-prem) to make CRISPR gene editing easy and cost-effective. With their platform, DESKGEN, scientists can...

Boundary Capital invests in Disruptive Antimicrobial Technology

May 12, 2016adminUncategorized

Boundary Capital has announced its latest investment in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms including bacteria and fungi with little prospect of them being able to develop resistance. Toxibact has a novel potential antimicrobial therapy for the treatment of all bacteria – both ‘gram positive’ and...

Boundary Capital invests in Ground-breaking Alzheimer’s Therapeutic Technology

April 28, 2016adminUncategorized

Boundary Capital has announced its latest investment in AB-Polyblok, a revolutionary technology which has the potential to treat, and potentially partially reverse, the effects of Alzheimer’s Disease. AB-Polyblock has a novel potential drug therapy for the treatment of Alzheimer’s Disease. The drug was conceived and developed after independent, private research. Alzheimer’s Disease is the largest...

1 2

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.